Agios Pharmaceuticals (AGIO)

• Market cap: $2.56B
• 1 day: 3.13%
• 5 days: 6.95%
• 1 month: 9.02%
• 3 months: 19.6%
• 6 months: 56.51%
• Year to date: 37.78%
• 1 year: -20.81%
• 5 years: 9.89%
• 10 years: -25.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Employees: 488